BBLG

distress 3/10 · well-funded / low risk

$1.100%today-64% from 52w high

bonebiologics.com2 employeesFounded 2004Burlington, MABiotechnology

Lead: spinal fusion

Revenue

pre-revenue

Liquidity

$0M

Runway

—

Shares 1y

Price & events

-37.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.0%

-8.3%

-20.3%

-18.5%

-36.4%

-64.1%

-85.3%

—

-100.0%

All

Overview

Market Cap: $1.97M
Volume: 3.85K
52 Week Range: $1.08 – $3.06
Total Shares: 1.80M
Float Shares: 1.79M
Short %: 3.75%
% Held by Insiders: 0.04%
% Held by Institutions: 0.25%
RVOL: 0.04x
Beta: 0.53

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

by year-end 2026enrollment completesecondaryPhase 1NB1 · Complete patient enrollment in first-in-human pilot studySEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,795,260 · 1 offerings/1y · 1 PIPEs

2026-07-17S-3shelf_registration
2026-07-098-Kprivate_placement
2026-03-13424B5offering
2025-09-02EFFECTshelf_effective
2025-08-29S-3/Ashelf_registration
2025-06-308-Kmaterial_agreement
2025-06-30424B4offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $12 (+1009% upside) · 1 analysts

no recent rating changes

Competitors — spinal fusion

none identified